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Abstract
IMPORTANCE—Data from an autosomal dominant Alzheimer disease (ADAD) kindred were 
used to track the longitudinal trajectory of cognitive decline associated with preclinical ADAD and 
explore factors that may modify the rate of cognitive decline.
OBJECTIVES—To evaluate the onset and rate of cognitive decline during preclinical ADAD and 
the effect of socioeconomic, vascular, and genetic factors on the cognitive decline.
DESIGN, SETTING, AND PARTICIPANTS—We performed a retrospective cohort study from 
January 1, 1995, through June 31, 2012, of individuals from Antioquia, Colombia, who tested 
positive for the ADAD-associated PSEN1 E280A mutation. Data analysis was performed from 
August 20, 2014, through November 30, 2015. A mixed-effects model was used to estimate annual 
rates of change in cognitive test scores and to mark the onset of cognitive decline.
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MAIN OUTCOMES AND MEASURES—Memory, language, praxis, and total scores from the 
Consortium to Establish a Registry for Alzheimer Disease test battery. Chronologic age was used 
as a time scale in the models. We explore the effects of sex; educational level; socioeconomic 
status; residence area; occupation type; marital status; history of hypertension, diabetes mellitus, 
and dyslipidemia; tobacco and alcohol use; and APOE ε4 on the rates of cognitive decline.
RESULTS—A total of 493 carriers met the inclusion criteria and were analyzed. A total of 256 
carriers had 2 or more assessments. At the time of the initial assessment, participants had a mean 
(SD) age of 33.4 (11.7) years and a mean (SD) educational level of 7.2 (4.2) years. They were 
predominantly female (270 [54.8%]), married (293 [59.4%]), and of low socioeconomic status 
(322 [65.3%]). Word list recall scores provided the earliest indicator of preclinical cognitive 
decline at 32 years of age, 12 and 17 years before the kindred’s respective median ages at mild 
cognitive impairment and dementia onset. After the change point, carriers had a statistically 
significant cognitive decline with a loss of 0.24 (95% CI, −0.26 to −0.22) points per year for the 
word list recall test and 2.13 (95% CI, −2.29 to −1.96) points per year for total scores. Carriers 
with high educational levels had an increase of approximately 36% in the rate of cognitive decline 
after the change point when compared with those with low educational levels (−2.89 vs −2.13 
points per year, respectively). Onset of cognitive decline was delayed by 3 years in individuals 
with higher educational levels compared with those with lower educational levels. Those with 
higher educational level, middle/high socioeconomic status, history of diabetes and hypertension, 
and tobacco and alcohol use had a steeper cognitive decline after onset.
CONCLUSIONS AND RELEVANCE—Preclinical cognitive decline was evident in PSEN1 
E280A mutation carriers 12 years before the onset of clinical impairment. Educational level may 
be a protective factor against the onset of cognitive impairment.
Research diagnostic criteria have been published for preclinical Alzheimer disease (AD) 
based on biomarkers of AD-related neurodegeneration.1 The study of carriers of AD-causing 
mutations provides a unique opportunity to characterize the preclinical changes associated 
with predisposition to AD.
For more than 25 years, the Neuroscience Group of Antioquia has studied a large kindred 
with autosomal dominant AD (ADAD) due to a single PSEN1 E280A mutation (OMIM 
104311.0009). Carriers from this kindred have an onset of mild cognitive impairment (MCI) 
at the age of 44 years and an onset of dementia at the age of 49 years.2 Previous studies3–9 
have found that carriers have brain Aβ plaque deposition and cerebrospinal fluid (CSF) and 
plasma biomarker evidence of Aβ overproduction decades before clinical symptoms. 
Cognitive markers also have been reported during preclinical stages of ADAD.10 However, 
given the heterogeneity of the cognitive profile of AD, it has been challenging to 
characterize cognitive changes that precede the onset of clinical impairment and to evaluate 
factors that may modify the rate and onset of cognitive decline during preclinical AD. Some 
of these factors, including genetic factors,11 educational level,12 socioeconomic status 
(SES),13 history of vascular disease (eg, hypertension, diabetes mellitus),14 and tobacco or 
alcohol use,14 have been related to cognitive decline. Preclinical cognitive markers and early 
detection of AD are increasingly important as research on new treatments that may slow or 
halt cognitive decline in AD is under way.15
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In this study, we tracked the longitudinal trajectory of cognitive changes for a period of 18 
years in preclinical PSEN1 E280A mutation carriers from Antioquia, Colombia. In addition, 
we estimated the onset and rate of cognitive decline during preclinical AD and the effect of 
socioeconomic, vascular, and genetic factors on the rate of cognitive decline.
Methods
Study Design and Participants
Participants who tested positive for the ADAD-associated PSEN1 E280A mutation were 
enrolled from January 1, 1995, through June 31, 2012.2 Data analysis was performed from 
August 20, 2014, through November 30, 2015. We included retrospective and longitudinal 
data from those carriers 18 years and older who had a complete neuropsychological 
assessment using the Consortium to Establish a Registry for Alzheimer Disease (CERAD) 
test battery. We excluded participants with a history of psychiatric disorders, illiteracy, 
stroke, epilepsy, traumatic brain injury, kidney failure, human immunodeficiency syndrome 
or AIDS, or substance abuse. All participants agreed to take part in this study and provided 
written informed consent before data collection. This study was approved by the ethics 
research committee of the University of Antioquia, Antioquia, Colombia. During clinical 
and neuropsychological assessments, physicians were masked to genetic status of the 
participants with no evident clinical symptoms to minimize the information bias. The 
genetic status was recorded in a database. Only the database’s coordinator (a system 
engineer) provided the genetic status for statistical analysis, with the name of the participant 
presented as a numerical code and not a name.
Procedures
All participants underwent comprehensive clinical and neuropsychological assessments. 
These assessments included an interview and medical and neuropsychological examinations. 
Medical examinations were performed by a neurologist or a physician trained in dementia 
assessment. Neuropsychological tests were conducted by psychologists. The 
neuropsychological protocol included the Mini-Mental State Examination (MMSE)16 and 
the CERAD test battery, which have been validated in our population.2,17 Clinical Dementia 
Rating (CDR)18 was used to establish the presence or absence of dementia. A CDR score of 
0 indicates cognitive normality; 0.5, very mild dementia; 1, mild dementia; 2, moderate 
dementia; and 3, severe dementia.
Demographic Information
Socioeconomic status was defined according to the Colombian government classification 
system as low or middle/high. Our cohort comes from a population with a low educational 
level; accordingly, we classified educational level into 2 groups based on the median years of 
formal education: high (≥7 years) and low (<7 years). Marital status was classified in 3 
groups: married or cohabitant, single, and divorced or widowed. Occupation was classified 
into 2 groups based on the nature of the work: manual work (housewives, farmers, domestic 
service employees, or technician) or nonmanual work (all professionals and managers, 
higher administrators, or clerical employees). Place of residence was classified as urban or 
rural.
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Cardiovascular Factors
Hypertension was considered to be present if systolic blood pressure was 140 mm Hg or 
higher or diastolic blood pressure was 90 mm Hg or higher in the clinical assessment or if 
medications for hypertension were prescribed or self-reported. History of dyslipidemia was 
defined based on self-reports, the use of cholesterol-lowering agents, or a total cholesterol 
level greater than 200 mg/dL (to convert to millimoles per liter, multiply by 0.0259) 
registered in the clinical record. History of diabetes or alcohol or tobacco use was defined 
based on patient self-report.
Genetic Analyses
Genomic DNA was extracted from blood by standard protocols, and PSEN1 E280A 
characterization was performed as previously described.19 For exploratory analyses, APOE 
genotyping was performed in a subsample of 130 mutation carriers following methods 
previously described.20 Given the low frequency of the ε2/3, ε2/4, and ε4/4 genotypes, data 
were classified into 2 categories (presence or absence of APOE ε4) for statistical analyses.19
Cognitive Outcomes
Memory, language, and praxis tests from the CERAD test battery were included, and a total 
score (CERADts) was calculated using the Chandler method21 (range, 0–100) by adding the 
scores of the CERAD subtests (verbal fluency, 15-item Boston Naming Test, word list 
memory, word list recall, word list recognition [discrimination], and constructional praxis).
Statistical Analysis
We estimated the statistical power of 90%22 to detect a relative effect size of 0.30 (assuming 
a relative β coefficient related to time variable or other covariable in the model), with 162 
participants and 3 or more assessments per individual assuming an intraclass correlation 
coefficient of 0.70 and a type I error of 0.05.
A mixed-effects model22 was used to estimate the annual rate of cognitive decline. Previous 
reports23,24 support the assumption that cognitive decline is not a constant linear process. 
Instead, the rate of cognitive decline increases after an unknown change point (CP) many 
years before clinical symptoms.25 Indeed, previous studies have also found differences in 
cross-sectional analyses between asymptomatic carriers and noncarriers in several 
biomarkers5 and cognitive markers2,10 at different preclinical stages. Thus, a CP approach 
provides an indirect estimation of when that cognitive decline could start. The approach 
taken by Hall et al23 was used to estimate the CP or onset of cognitive decline. The models 
used allow estimation of the rate of cognitive decline before and after the CP. To give an 
interpretation of the constant in the model, age was centered at 20 years. Fifty models were 
adjusted by varying the CP annually between the ages of 18 and 60 years. The likelihood 
approach was used to compare the models23 based on the goodness-of-fit index as the 
Akaike information criterion and the Bayesian information criterion.26 The lowest Bayesian 
information criterion was accepted as appropriate. The effect of sex, SES, educational level, 
vascular factors, tobacco or alcohol use, and APOE ε4 on cognition was analyzed using the 
MMSE score, CERAD subtest scores, and CERADts. The interaction coefficient between 
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age (as a time variable) and demographic and vascular factors was analyzed in the model to 
estimate the annual rate of change in the presence or absence of those factors.
Results
Participants
From 703 PSEN1 E280A mutation carriers, 210 were excluded. A total of 493 carriers met 
the inclusion criteria and were analyzed (eFigure 1 in the Supplement). There were 256 
carriers with 2 or more assessments, the median time between assessments was 2 years 
(interquartile range, 1–3 years), and the median time of follow-up was 5 years (interquartile 
range, 3–10 years). At the time of the initial assessment, participants had a mean (SD) age of 
33.4 (11.7) years and a mean (SD) educational level of 7.2 (4.2) years. They were 
predominantly female (270 [54.8%]), married (293 [59.4%]), and of low SES (322 [65.3%]). 
A total of 432 participants (87.6%) had manual work occupations, 43 (8.7%) had a history 
of hypertension, 33 (6.7%) had dyslipidemia, and 8 (1.6%) had diabetes. A total of 123 
participants (24.9%) had a history of tobacco use, and 58 (11.8%) had a history of alcohol 
use. The mean MMSE score was 26.5, and 386 (78.3%) were cognitively normal (CDR, 0). 
A subsample of 130 PSEN1 mutation carriers underwent APOE genotyping; 36 (27.7%) 
tested positive for at least one ε4 allele (APOE ε4) (Table 1).
Description and Estimate of Cognitive Decline
Figure 1 shows the spaghetti plot for CERADts (eFigure 2 in the Supplement illustrates the 
MMSE and CERAD subtests). The goodness-of-fit indexes suggested a CP for CERADts at 
the age of 34 years. Word list recall scores provided the earliest indication of cognitive 
decline at the age of 32 years, followed by word list learning, word list recognition, verbal 
fluency, and naming at the age of 34 years and constructional praxis at the age of 38 years 
(eFigure 3 in the Supplement shows the Akaike and Bayesian goodness-of-fit indexes for the 
models). Table 2 gives the coefficients of the estimated cognitive decline before and after the 
CP for the CERADts, MMSE, and CERAD subtests. After the CP, the CERADts revealed a 
statistically significant cognitive decline with a loss of 2.13 (95% CI, −2.29 to −1.96) points 
per year.
Onset of cognitive decline on the word list recall test was delayed by 3 years in individuals 
with a high educational level (minimum Akaike information criterion, 2949) when compared 
with those with a low educational level (minimum Akaike information criterion, 2115). 
Mutation carriers with high educational levels had a CP at the age of 37 years for CERADts; 
at the age of 38 years for the MMSE; at the age of 36 years for word list recall, word list 
learning, and word list recognition; at the age of 38 years for verbal fluency; and at the age 
of 39 years for naming and constructional praxis. Mutation carriers with low educational 
levels had a CP at the age of 35 years for CERADts; at the age of 36 years for the MMSE; at 
the age of 33 years for word list recall; at the age of 37 years for word list learning, word list 
recognition, and verbal fluency; and at the age of 38 years for naming and constructional 
praxis.
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Effects of Risk Factors on Cognitive Decline
Table 3 gives the coefficients of the estimated cognitive decline on CERADts in relation to 
the presence or absence of risk factors. Carriers with high educational levels had an increase 
of approximately 36% in the rate of cognitive decline after the CP when compared with 
those with low educational levels (−2.89 vs −2.13 points per year after adjustment). Similar 
results were found when cognitive decline was estimated in relation to SES, place of 
residence, diabetes, and tobacco or alcohol use (eTable 1, eTable 2, and eTable 3 in the 
Supplement estimate the cognitive decline in the MMSE and CERAD subtests). No 
statistical differences in the rate of cognitive decline were found after the CP in relation to 
sex, SES, occupation, residence area, marital status, and history of hypertension, diabetes, 
dyslipidemia, and tobacco and alcohol use.
Exploratory Analysis With APOE Genotype and Cognitive Decline
The frequency of APOE genotypes was as follows: APOE ε2/3, 11 patients; APOE ε2/4, 4 
patients; APOE ε3/3, 83 patients; and APOE ε3/4, 32 patients. No differences in cognitive 
decline on any measure were found between APOE ε4 carriers and APOE ε4 noncarriers. 
No statistically significant difference was found in frequency of APOE ε4 status in 
demographic or vascular factors (sex: P = 0.48; SES: P = 0.66; educational level: P = 0.72; 
occupation: P = 0.12; residence area: P = 0.61; marital status: P = 0.54; history of 
hypertension: P = 0.34; diabetes: P = 0.21; dyslipidemia: P = 0.94; tobacco use: P = 0.65; 
and alcohol use: P = 0.56).
Sensitivity Analysis
Results of the analysis that included participants with 2 or more assessments (n = 256) 
compared with the total sample (n = 493) provided similar results in the estimation of CP 
and the rate of cognitive decline. For all cognitive tests before the CP, coefficients in those 
carriers with 2 or more assessments were similar to coefficients in the total sample. We 
found similar results in the estimation of the CP (eFigure 4 in the Supplement), and 
thereafter there was a median increase of 4.5% in the rate of cognitive decline in all subtests 
(range, 3.2%–5.7%) (eTable 4 in the Supplement). Moreover, additional analysis in carriers 
with a CDR of 0 provided similar results in CP estimation (eFigure 5 in the Supplement).
Discussion
This study provides evidence of preclinical cognitive decline in PSEN1 mutation carriers as 
early as 12 years before the estimated median age at MCI diagnosis and 17 years before 
dementia diagnosis. A memory test score provided the earliest indicator of cognitive decline. 
A higher educational level was associated with a delay in onset of cognitive decline and also 
with more rapid cognitive decline after onset.
Previous studies in sporadic AD have found that cognitive decline begins at approximately 3 
years before MCI25 and between 3 and 9 years before dementia.27 On the basis of previous 
work at identifying early biomarkers3–5 and the prevailing model of preclinical AD 
biomarker trajectory,28 we propose a model (Figure 2) of this trajectory, including cognitive 
changes, from preclinical to clinical stages in ADAD due to the PSEN1 E280A mutation.3 
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According to this model, the first biomarker changes are evident as CSF Aβ1–42 
abnormalities at the age of 24 years (stage 1) followed by increased fibrillar Aβ 
accumulation at the age of 28 years (stage 2) and onset of cognitive decline at the age of 32 
years (stage 3).
In addition, high educational level delayed by 3 years the onset of cognitive decline. This 
finding is consistent with other studies12,29 reported for sporadic AD. The theory of 
cognitive reserve could explain our findings.30 Cognitive reserve has been conceptualized as 
a multifactor construct that may include educational level, SES, and occupation, as well as 
lifestyle factors, which may contribute to cognitive reserve as part of a more dynamic 
process that changes throughout life.30 Studies12,30 of cognitive reserve have found that 
older individuals whose life experiences include more daily, challenging cognitive activities 
may have more compensatory strategies in place before the onset of cognitive impairment. 
In contrast, an early study performed by Pastor et al19 with PSEN1 E280A mutation carriers 
found that those carriers with high educational levels had an earlier onset of dementia. Some 
explanations for these opposite results are the outcome and a potential information bias. 
Pastor et al19 analyzed as the primary outcome the diagnosis of dementia using time to event 
models, and in some patients the diagnosis could be delayed because the onset of dementia 
was defined from information provided by a relative.
The main strength of the present study is the longitudinal follow-up of members from a large 
ADAD kindred with a single-gene mutation, with characterized ages at the onset of MCI and 
dementia2 and previously characterized associations of brain imaging and CSF biomarkers 
in adulthood.3–5 Another strength is the opportunity to evaluate the influence of risk factors 
on AD-related cognitive decline and clinical onset independent of potentially confounding 
effects of older age and age-related disorders.
This study also had several limitations. Exposures were measured retrospectively from 
clinical records, which does not account for the accumulative process of exposure, 
frequency, duration, and severity. Our analyses did not include other factors associated with 
the risk of dementia or cognitive decline (eg, obesity, physical activity, diet, cognitive 
stimulation, or cognitive or behavior-modifying drugs, such as memantine hydrochloride) 
because these were not systematically assessed and collected during the clinical 
assessments. In addition, the period of cognitive decline is larger than the time of 
observations for each participant. In our cohort, the data from carriers with 2 or more 
assessments had a median of 2 years between assessments in a mean longitudinal length of 5 
years. Although mixed models can handle unbalanced design and missing data, the amount 
of information in our cohort limited the possibilities of more statistical analysis to determine 
how the CP varied among carriers. Further analysis is necessary, including a new cohort of 
carriers with a systematic assessment in the preclinical stage, to study how variation in the 
CP and the rate of cognitive decline between participants and how demographic, vascular, 
and other factors are related. Other methods using a Bayesian approach31 are necessary to 
find this variation. CERAD is sensitive to detect early changes associated with MCI.21 
However, the floor or ceiling effects of CERAD subtests may affect the sensitivity to 
evaluate cognitive decline in the preclinical stage. Our cohort comes from a population with 
a low educational level, which is an important limitation for comparison with other studies. 
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Finally, given the conditions of our sample, it is uncertain to what extent our findings may be 
generalizable to other AD-causing mutations and late-onset AD.
Conclusions
The systematic assessment of ADAD mutation carriers for more than 20 years is a unique 
opportunity to characterize the trajectory of some of the earliest preclinical changes and will 
guide future preventive interventions. Our findings suggest that cognitive decline could be 
detected by neuropsychological tests in preclinical AD more than a decade before the onset 
of clinical symptoms. Furthermore, our findings also support the idea that high educational 
level may be a protective effect against onset of cognitive decline.
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Key Points
Question
When is the onset of cognitive decline in the PSEN1 E280A carriers with autosomal 
dominant Alzheimer disease (ADAD)?
Findings
In this retrospective cohort study, which included 493 PSEN1 E280A carriers, a word list 
test provided the earliest indicator of preclinical cognitive decline at 32 years of age, 
which is 12 and 17 years before the kindred’s respective median ages at mild cognitive 
impairment and dementia onset.
Meaning
The systematic assessment of ADAD carriers for more than 20 years is a unique 
opportunity to characterize the trajectory of some of the earliest preclinical changes, 
which might guide future preventive interventions.
Aguirre-Acevedo et al. Page 11
JAMA Neurol. Author manuscript; available in PMC 2017 July 11.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
Spaghetti Plot for Longitudinal Assessment of the Consortium to Establish a Registry for 
Alzheimer Disease Total Score (CERADts) in PSEN1 E280A Mutation Carriers
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Figure 2. 
Model for Preclinical and Clinical Stage in PSEN1 E280A Mutation Carriers
CSF indicates cerebrospinal fluid; MCI, mild cognitive impairment; and PET, positron 
emission tomography.
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Table 1
Demographic and Clinical Characteristics of 493 PSEN1 E280A Mutation Carriers
Characteristic Finding (N = 493)a
Women 270 (54.8)
Age at first assessment, mean (SD), y 33.4 (11.7)
Educational level, mean (SD), y 7.2 (4.2)
Socioeconomic status
  Low 322 (65.3)
  Middle 166 (33.7)
  High 5 (1.0)
Occupation
  Nonmanual 61 (12.4)
  Manual 432 (87.6)
Residence area
  Urban 354 (71.8)
  Rural 139 (28.2)
Marital status
  Married or cohabitant 293 (59.4)
  Single 164 (33.3)
  Divorced or widowed 36 (7.3)
Vascular factors
  Hypertension 43 (8.7)
  Dyslipidemia 33 (6.7)
  Diabetes mellitus 8 (1.6)
  Tobacco use 123 (24.9)
  Alcohol use 58 (11.8)
APOE (n = 130)
  ε2/3 11 (8.5)
  ε2/4 4 (3.1)
  ε3/3 83 (63.8)
  ε3/4 32 (24.6)
MMSE score, mean (SD) 26.5 (5.5)
Clinical Dementia Rating
  0 386 (78.3)
  0.5 51 (10.3)
  1 43 (8.7)
  2 13 (2.7)
Abbreviation: MMSE, Mini-Mental State Examination.
a
Data are presented as number (percentage) of study participants unless otherwise indicated.
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Table 3
Cognitive Decline in CERADts by Risk Factors in 493 PSEN1 E280A Mutation Carriers
Characteristic
Raw Coefficient (95% CI) Adjusted Coefficient (95% CI)a
Before 34 Years Old After 34 Years Old Before 34 Years Old After 34 Years Old
Sex
  Female −0.28 (−0.46 to −0.10) −2.16 (−2.37 to −1.95) 0.11 (−0.11 to 0.33) −2.10 (−2.31 to −1.90)
  Male 0.46 (0.07 to 0.85) −2.24 (−2.75 to −1.72) 0.09 (−0.43 to 0.61) −2.15 (−2.66 to −1.65)
Educational levelb
  High (median years for formal 
education, ≥7)
0.11 (−0.08 to 0.29) −2.89 (−3.25 to −2.52) 0.12 (−0.08 to 0.32) −2.89 (−3.25 to −2.53)
  Low (median years of formal 
education, <7)
−0.04 (−0.28 to 0.19) −2.08 (−2.28 to −1.88) −0.08 (−0.34 to 0.18) −2.13 (−2.34 to −1.93)
Socioeconomic status
  Middle/high 0.14 (−0.12 to 0.40) −2.65 (−3.02 to −2.29) 0.17 (−0.09 to 0.43) −2.52 (−2.86 to −2.17)
  Low −0.07 (−0.74 to 0.59) −1.92 (−2.63 to −1.22) 0.04 (−0.59 to 0.68) −1.87 (−2.54 to −1.20)
Residence area
  Urban 0.00 (−0.19 to 0.19) −2.32 (−2.70 to −1.94) 0.14 (−0.06 to 0.33) −2.24 (−2.60 to −1.88)
  Rural −0.09 (−0.68 to 0.49) −1.87 (−2.61 to −1.12) 0.00 (−0.57 to 0.56) −1.84 (−2.56 to −1.12)
Occupation type
  Nonmanual 0.07 (−0.86 to 0.99) −1.47 (−1.97 to −0.97) 0.02 (−0.88 to 0.93) −1.48 (−1.95 to −1.02)
  Manual 0.08 (−0.87 to 1.04) −2.20 (−3.64 to −0.76) 0.11 (−0.79 to 1.01) −2.15 (−3.53 to −0.77)
Marital status
  Single 0.08 (−0.55 to 0.72) −2.49 (−3.12 to −1.86) 0.33 (−0.32 to 0.99) −2.13 (−2.77 to −1.49)
  Married 0.14 (−0.10 to 0.38) −2.15 (−2.33 to −1.97) 0.39 (0.10 to 0.68) −1.93 (−2.14 to −1.73)
Hypertension
  Present 0.30 (−1.28 to 1.87) −2.24 (−2.86 to −1.63) 0.73 (−0.84 to 2.29) −2.04 (−2.67 to −1.40)
  Absent 0.00 (−1.39 to 1.39) −2.20 (−2.63 to −1.77) 0.37 (−0.94 to 1.68) −1.94 (−2.36 to −1.53)
Dyslipidemia
  Present 0.16 (−1.08 to 1.41) −1.74 (−2.39 to −1.10) 0.30 (−0.91 to 1.51) −1.61 (−2.27 to −0.94)
  Absent 0.02 (−0.17 to 0.20) −2.28 (−2.46 to −2.10) 0.38 (0.12 to 0.64) −2.02 (−2.23 to −1.81)
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Characteristic
Raw Coefficient (95% CI) Adjusted Coefficient (95% CI)a
Before 34 Years Old After 34 Years Old Before 34 Years Old After 34 Years Old
Diabetes mellitus
  Present 1.72 (−2.51 to 5.96) −3.10 (−4.45 to −1.75) 1.27 (−2.74 to 5.28) −2.60 (−3.93 to −1.28)
  Absent 0.00 (−0.18 to 0.18) −2.19 (−2.35 to −2.02) 0.37 (0.12 to 0.63) −1.95 (−2.14 to −1.75)
Tobacco use
  Present 0.00 (−0.54 to 0.54) −2.41 (−2.62 to −2.20) 0.50 (−0.09 to 1.10) −2.18 (−2.41 to −1.95)
  Absent 0.01 (−0.19 to 0.21) −2.05 (−2.26 to −1.85) 0.35 (0.09 to 0.61) −1.83 (−2.06 to −1.60)
Alcohol use
  Present −0.14 (−0.94 to 0.66) −2.57 (−3.19 to −1.94) 0.53 (−0.29 to 1.35) −2.44 (−3.08 to −1.81)
  Absent −0.01 (−0.62 to 0.61) −2.09 (−2.53 to −1.65) 0.37 (−0.20 to 0.93) −1.85 (−2.28 to −1.43)
APOE ε4
  Present −0.66 (−2.19 to 0.87) −2.16 (−3.00 to −1.33) −0.26 (−2.01 to 1.49) −2.31 (−3.33 to −1.29)
  Absent 0.20 (−0.39 to 0.79) −2.58 (−2.88 to −2.28) 0.37 (−0.37 to 1.11) −2.45 (−2.82 to −2.08)
Abbreviations: CERADts, Consortium to Establish a Registry for Alzheimer’s Disease total score; CP, change point.
aAdjusted coefficients by sex, educational level, socioeconomic status, residence area, occupation type, marital status, hypertension, dyslipidemia, 
diabetes mellitus, and tobacco and alcohol use.
b
The CP by educational level: high (CP, 37 years old) or low (CP, 35 years old).
JAMA Neurol. Author manuscript; available in PMC 2017 July 11.
